Research

IUD in hand

Research projects are continuously being developed and implemented within the Family Planning Division. Past and present research includes evaluating the effectiveness and satisfaction of a levonorgestrel-releasing intrauterine system (IUD) for long-term, reversible contraception and the effectiveness of the insertion device. Faculty members within the Obstetrics & Gynecology department have developed a semi-quantitative pregnancy test that is being studied for post-abortion care and in vitro fertilization (IVF) treatment, and a dedicated IUD inserter for use in post delivery settings both domestically and internationally.

Fellowship research projects have included simplifying methods for IUD insertion and improving patient access and experience during 2nd trimester pregnancy termination by evaluating the effectiveness of Mifepristone during treatment.

For more information about any current or past research projects, please email: birthcontrol@stanford.edu.

For inquiries about potential collaboration, please email: fpresearch@stanford.edu.

Recruiting

A Phase 3, Multicenter, Open-Label Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding

The objective of this study is to assess the effectiveness of the Medicines360 levonorgestrel 52 mg IUS, Liletta, as a treatment for heavy menstrual bleeding.

This study is actively recruiting healthy women 18-50 years of age who are seeking treatment for heavy menstrual bleeding and do not wish to become pregnant for 10 months. If you are interested in participating in this research, please fill out the form at the following site https://trials.autocruitment.com/forms/HeavyMenstrualBleedingStudy/ and one of our research staff will contact you with further information.

Principal Investigator: Kate A. Shaw, MD, MSc

Prospective Multi-Center Office-Based Bi-Lateral Tubal Occlusion Trial for Female Permanent Contraception (BLOC) 

The objective of this study is to evaluate the safety and effectiveness of the FemBloc Permanent Contraceptive System for female sterilization in preventing pregnancy and to compare safety and satisfaction measures in women undergoing FemBloc sterilization with women undergoing laparoscopic bilateral tubal sterilization. 

This study is actively recruiting patients. If you are interested in participating in this research, please fill out the form at the following site www.fembloc.com and one of our research staff will contact you with further information.

Principal Investigator: Paul Blumenthal, MD, MPH

Screening for Cervical Intraepithelial Neoplasia Using Self-Collected Menstrual Blood

The purpose of this study is to investigate the feasibility and efficacy of assessing HR-HPV DNA and HPV E6/E7 mRNA via self-collected menstrual blood in a menstrual pad.

This study is actively recruiting patients 18-45 years of age presenting to Stanford gynecology clinic with a history of positive HPV tests. Please email birthcontrol@stanford.edu for more information.

Principal Investigator: Paul Blumenthal, MD, MPH 

Cervical Preparation Using Ulipristal Acetate in Second Trimester Surgical Abortions

The objective of this pilot study is to test the feasibility of using ulipristal, an oral medication similar to Mifepristone, as a medical form of cervical preparation prior to surgical abortion.

This study is actively recruiting patients presenting to Stanford gynecology clinic for second trimester surgical abortions. Please email birthcontrol@stanford.edu for more information.

Principal Investigator: Sarah Peterson, MD

Ongoing

A Phase 3, Prospective, Multi-Center, Single-Arm, Open Label Study to Evaluate VeraCept, a Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety and Tolerability

The primary objective of the study is to assess the contraceptive efficacy (prevention of pregnancy) of VeraCept, a birth control device that is inserted in the uterus. VeraCept is a non-hormonal (does not contain hormones), low-dose, copper-releasing IUD.

This study is ongoing and no longer recruiting participants. For more information, please email birthcontrol@stanford.edu.

Principal Investigator: Paul Blumenthal, MD, MPH

Comparative Study of Menstrual Blood and Systemic Blood: Qualifying the Difference

The objective of this study is to investigate how menstrual blood differs from systemic blood to evaluate if menstrual blood could be utilized as a natural and non-invasive access to blood for regular health monitoring and early diagnostics.

This study is ongoing and currently recruiting participants. Please email birthcontrol@stanford.edu for more information.

Principal Investigator: Paul Blumenthal, MD, MPH

On Demand Contraception: Investigating Efficacy of Ulipristal Acetate plus a COX-2 Inhibitor at Peak Fertility

The objective of this study is to learn if the combination of Ulipristal Acetate and a COX-2 inhibitor can prevent ovulation (release of an egg) in order to provide more contraceptive (birth control) options to women. 

This study is ongoing and no longer recruiting participants. Please email birthcontrol@stanford.edu for more information. 

Principal Investigator: Erica Cahill, MD

Labor and Delivery Implant Insertion (LADII): A randomized controlled trial

The objective of this study is to compare the immediate insertion of the contraceptive implant to delayed insertion (before hospital discharge following delivery) and breastfeeding outcomes between timing of insertion.

This study is ongoing and currently recruiting patients presenting to labor and delivery who desire a contraceptive implant for postpartum contraception. Please contact us for more information birthcontrol@stanford.edu.

Principal Investigator: Kate A. Shaw, MD, MSc

12 versus 20 mL Paracervical Block for Pain-Control During Cervical Preparation for Dilation and Evacuation: A Single-Blinded Randomized Controlled Trial

This study seeks to compare a 12 mL, 2-site 1% plain lidocaine paracervical block for pain control during cervical preparation (osmotic dilator insertion) for Dilation and Evacuation (D&E) to a 20 mL 1% lidocaine 2-site paracervical block. The primary outcome of this study is participant perceived pain associated with cervical preparation for D&E.

This study is ongoing and currently recruiting patients presenting to Stanford gynecology clinic for cervical preparation for D&E. Please email birthcontrol@stanford.edu for more information. 

Principal Investigator: Kate A. Shaw, MD, MSc

Transcutaneous Electrical Nerve Stimulation (TENS) for Pain Control During First Trimester Abortion: A blinded randomized controlled trial

The objective of this study is to learn if transcutaneous electrical nerve stimulation is an acceptable alternative to moderate sedation with intravenous pain control with first trimester surgical abortion.

This study is ongoing and currently recruiting patients presenting to Planned Parenthood for a first trimester surgical abortion. Please email birthcontrol@stanford.edu for more information. 

Principal Investigator: Kate A. Shaw, MD, MSc

A Phase 3, Multi-Center, Open-Label Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception

The purpose of this study is to assess the efficacy of a levonorgestreal-releasing intrauterine system (LNG20) in nulliparous and parous women of child-bearing potential who request long-term, reversible contraception.

This is an ongoing study that is no longer recruiting patients. Please email birthcontrol@stanford.edu for more information. 

Principal Investigator: Paul D Blumenthal, MD, MPH

Multi-center, open-label, uncontrolled study to assess contraceptive efficacy and safety of Mirena during extended use beyond 5 years in women 18 to 35 years of age including a subgroup evaluation of treatment effect on heavy menstrual bleeding

The primary objective of this study is to assess the contraceptive efficacy of Mirena beyond 5 years up to 8 years of use. Secondary objectives are the assessment of menstrual blood loss in women who had the Mirena inserted for the indication of heavy menstrual bleeding.

This is an ongoing study that is no longer recruiting patients. Please email birthcontrol@stanford.edu for more information.

Principal Investigator: Paul D Blumenthal, MD, MPH